TEVA - Teva Pharmaceutical Industries Limited
| Previous close | 23.290 |
| Open | 23.340 |
| Bid | 23.230 x 2900 |
| Ask | 23.240 x 4000 |
| Day's range | 23.100 - 23.510 |
| 52-week range | 10.850 - 33.240 |
| Volume | 3,532,613 |
| Avg. volume | 11,441,241 |
| Market cap | 23.664B |
| Beta | 1.11 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -15.793 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 2017-11-27 |
| 1y target est | 20.43 |
Market Realist•6 hours agoFDA Recalls Valsartan Drugs on Impurity Concerns: Teva Fell 1.8%
On July 13, the FDA announced a voluntary recall of drugs containing valsartan and valsartan/hydrochlorothiazide API (active pharmaceutical ingredient) manufactured by Solco Healthcare, Major Pharmaceuticals, and Teva Pharmaceutical (TEVA). The drugs are used for the treatment of heart failure and high blood pressure.
- Motley Fool•22 hours ago
Here's How Teva Pharmaceuticals Pulled Off a 28.3% Gain in the First Half of 2018
Demand for generic drugs is on the rise, and investors are convinced the trend will keep this profitable company moving in the right direction.
- Motley Fool•3 days ago
3 Warren Buffett Stocks Worth Buying Now
These three stocks are backed by Buffett and Berkshire and could help power your portfolio to market-beating returns.
- MarketWatch•3 days ago
FDA recalls heart drugs made by Teva, others over carcinogen impurity
The Food and Drug Administration issued a voluntary recall late Friday of high-blood pressure and heart drugs containing the ingredient valsartan because of impurity issues. Affected companies include Teva Pharmaceuticals Industries Ltd. (teva) Solco Healthcare, and Major Pharmaceuticals, the FDA said. The agency said valsartan used in the affected products contained N-nitrosodimethylamine, which is classified as a probable human carcinogen.
- Zacks•3 days ago
4 Warren Buffett Stocks to Buy in Q2 Earnings
We highlight four of the Oracle of Omaha's sought-after companies that are likely to report upbeat second-quarter earnings.
- Zacks•5 days ago
Has Teva Pharmaceutical Industries (TEVA) Outpaced Other Medical Stocks This Year?
Is (TEVA) Outperforming Other Medical Stocks This Year?
- Business Wire•5 days ago
Teva to Report Second Quarter 2018 Financial Results on August 2, 2018
Teva Pharmaceutical Industries Ltd. (TEVA) announced today that it will release its second quarter 2018 financial results on Thursday, August 2, 2018 at 7:00 a.m. ET. Teva will host a conference call and live webcast on the same day, at 8:00 a.m. ET to discuss its second quarter 2018 results and overall business environment.
Market Realist•6 days agoTeva Announces Launch of Generic Version of Uceris in US
On July 9, Teva announced the launch of its generic Uceris (budesonide) extended-release tablets (nine milligrams) in the United States. In November 2017, Teva prevailed in its litigation challenging Valeant Pharmaceuticals’ (VRX) Uceris patent, which was acquired through the acquisition of Salix in 2015. Teva was the first applicant to file an ANDA (abbreviated new drug application) for generic Uceris.
- Associated Press•7 days ago
Correction: Teva-US-HQ Move story
TRENTON, N.J. (AP) — In a story July 6 about Teva Pharmaceuticals moving its U.S. headquarters to New Jersey, The Associated Press erroneously reported the amount in tax credits the firm is receiving. The state's Economic Development authority approved about $40 million in credits over 10 years, not about $4 million in total credits over that period.
- Business Wire•7 days ago
Teva Announces Launch of a Generic Version of Uceris® in the United States
Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the launch of a generic version of Uceris®1 (budesonide) extended-release tablets, 9 mg, in the U.S. Budesonide extended-release tablets are a glucocorticosteroid indicated for the induction of remission in patients with active, mild to moderate ulcerative colitis. “The launch of generic budesonide extended-release tablets signals an important addition to Teva’s portfolio,” said Brendan O’Grady, EVP and head of North America Commercial.
- Zacks•7 days ago
TEVA or AKRX: Which Is the Better Value Stock Right Now?
TEVA vs. AKRX: Which Stock Is the Better Value Option?
Market Realist•7 days agoCan Teva’s Fremanezumab Revert Chronic Migraine to Episodic?
As we saw in the previous part of this series, Teva presented new data on fremanezumab at the AHS (American Headache Society) 60th Annual Scientific Meeting in San Francisco. It is one of Teva’s key pipeline drugs and is expected to be a key growth driver for the company. Teva’s specialty products pipeline is provided in the graph below.
Market Realist•7 days agoTeva Presented New Data on Fremanezumab: What You Should Know
During the AHS (American Headache Society) 60th Annual Scientific Meeting in San Francisco, which was held from June 28 to July 1, Teva presented new data on its much-awaited migraine drug fremanezumab. Teva has a September PDUFA (Prescription Drug User Fee Act) date for the drug. On June 15, the company provided an update on the drug’s Enforce Phase 3 clinical development program for cluster headaches.
Market Realist•10 days agoTeva Pharmaceutical Stock in the Week Ended July 6
On July 5, Teva Pharmaceutical Industries (TEVA) stock ended the trading day at $23.92, a fall of 3.2% compared to the previous day. TEVA stock was trading 121% higher than its 52-week low of $10.85 on November 2, 2017. Currently, Teva Pharmaceutical stock is trading higher than its 50-day moving average of $22.56 as well as its 200-day moving average of $19.85.
Market Realist•10 days agoAnalyst Recommendations for Teva Pharmaceutical in July
Teva Pharmaceutical Industries (TEVA) is one of the largest generic drug manufacturers. It has been recuperating from its recent troubles as it started facing generic competition for its key product Copaxone. Warren Buffet’s Berkshire Hathaway initiated investment in Teva in the previous quarter and increased it in the recently reported quarter.
- CNBC•14 days ago
Virtual doctor start-up American Well is raising over $300 million and Philips is a new investor
American Well is raising over $300 million for telemedicine, and Philips is a new investor
- Market Realist•18 days ago
Teva to Present New Data for Fremanezumab
Today, Teva Pharmaceutical Industries (TEVA) announced that it will present new data for its migraine drug Fremanezumab, which is under review by the FDA for the preventive treatment as a monthly or quarterly injection, at the AHS’s (American Headache Society) 60th Annual Scientific Meeting in San Francisco. The event is being held from June 28 to July 1. Teva plans to present 23 abstracts, three oral presentations, and one late-breaking poster of Fremanezumab.
- Business Wire•18 days ago
Teva to Present New Fremanezumab Data, Including Long-Term Data, at the American Headache Society’s 60th Annual Scientific Meeting
Teva Pharmaceutical Industries Ltd. today announced 23 abstracts, one late-breaking poster and three oral presentations of fremanezumab for the preventive treatment of migraine which will be presented at the American Headache Society’s 60th Annual Scientific Meeting in San Francisco from June 28-July 1, 2018.
- Investing.com•19 days ago
Stocks - ConAgra, Pinnacle Foods Tumble in Pre-Market, WWE Surges
Investing.com - Stocks in focus in pre-market trade Wednesday:
- Motley Fool•20 days ago
3 Best Big Pharma Stocks of 2018 So Far
Are any of these biggest year-to-date winners smart picks for the long term?
- Reuters - UK Focus•27 days ago
EU mergers and takeovers (June 19)
The following are mergers under review by the European Commission and a brief guide to the EU merger process: APPROVALS AND WITHDRAWALS -- Japanese trading company Sumitomo Corp and Sumitomo Mitsui Financial ...
Market Realist•27 days agoAnalysts Raise Their 12-Month Target Price on Teva Pharmaceutical
On June 11, Leerink raised its 12-month target price on Teva from $13 to $16 while maintaining its “underperform” rating on the stock. Leerink analyst Ami Fadia revised the target prices to better reflect the improving dynamics of the company.
- Zacks•28 days ago
Teva to Discontinue a Fremanezumab Study on Cluster Headache
Teva decides to halt a phase III study, evaluating fremanezumab for the treatment of chronic cluster headache, following an interim analysis, which anticipates that the study is unlikely to meet its endpoint.
- Market Realist•28 days ago
A Look at Teva’s Generic Drugs Research Pipeline
Teva Pharmaceutical Industries (TEVA) is the largest generics pharma manufacturer in the world. In particular, the FDA is approving generics versions of branded drugs more rapidly to shift toward a more affordable healthcare structure. Teva is on track to achieve targeted cost reductions and revenue growth.
- Investor's Business Daily•last month
Teva Scraps A Study In Cluster Headaches — And This Rival Benefits
Alder Biopharmaceuticals gapped up Friday after rival Teva Pharmaceutical scrapped a late-stage study in chronic cluster headaches.
